Macquarie Group LTD Castle Biosciences Inc Transaction History

Macquarie Group LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$22.51 - $34.32 $10,714 - $16,336	-476 Reduced 35.9%	850 $35,000
Q2 2022 Aug 15, 2022	SELL	$16.0 - $45.99 $10.5 Million - $30.2 Million	-657,400 Reduced 99.8%	1,326 $29,000
Q1 2022 May 16, 2022	BUY	$33.17 - $46.98 $72,111 - $102,134	2,174 Added 0.33%	658,726 $29.6 Million
Q4 2021 Feb 11, 2022	SELL	$39.06 - $67.58 $488,601 - $845,358	-12,509 Reduced 1.87%	656,552 $28.1 Million
Q3 2021 Nov 12, 2021	BUY	$60.13 - $77.6 $10.8 Million - $13.9 Million	178,844 Added 36.48%	669,061 $44.5 Million
Q2 2021 Aug 13, 2021	BUY	$50.07 - $76.78 $24.5 Million - $37.6 Million	489,719 Added 98337.15%	490,217 $35.9 Million
Q1 2021 May 14, 2021	BUY	$58.92 - $97.33 $16,379 - $27,057	278 Added 126.36%	498 $34,000
Q2 2020 Aug 11, 2020	BUY	$27.28 - $43.01 $6,001 - $9,462	220 New	220 $8,000

171

25.5M

511K

130K

Ticker CSTL
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 26,297,000
Market Cap $750M
Description
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

Stay updated on Macquarie Group LTD with notifications on news.